CTOs on the Move

Access Integrated Healthcare

www.accessih.com

 
Founded by Chief Executive Officer Sam Solakyan, Global Holdings, Inc. has excelled in its journey in becoming leaders in each of the industries it has a presence in. Their main responsibility lies in providing their clients with the most premiere level of service. More than just your typical holdings group, Global is a multifaceted company with financial assets and ownership in the radiology, pharmaceuticals, and medical billing and collections industries. Instead of merely buying and selling companies like other holdings groups, Global searches for the less desirable companies with hidden potential and applies its knowledge and expertise in the management ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.accessih.com
  • 550 N. Brand Blvd. 20th Floor
    Glendale, CA USA 91203
  • Phone: 866.460.7465

Executives

Name Title Contact Details

Similar Companies

AcelRx

AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.

Capital Health Plan

Capital Health Plan is a Tallahassee, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PTPN

PTPN is a Calabasas, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hialeah Technology Center

Hialeah Technology Center is a Hialeah, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Simulation and Training Environment Laboratory

Simulation and Training Environment Laboratory is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.